title: Defective neurite extension is caused by a mutation in amyloid beta/A4 (A beta) protein precursor found in familial Alzheimer's disease.
abstract: Clonal central nervous system neuronal cells, B103, do not synthesize detectable endogenous APP or APLP. B103 cells transfected with both wild-type (B103/APP) and mutant APP construct (B103/APP delta NL) secreted comparable amounts of soluble forms of APP (sAPP). B103/APP cells produced sAPP and cleaved at amyloid beta/A4 (A beta) 16, the alpha-secretase site, and B103/APP delta NL cells produced sAPP beta cleaved at A beta 1, the beta-secretase site. B103/APP delta NL cells developed fewer neurites than B103/APP cells in a serum-free defined medium. Neurite numbers of parent B103 cells were increased by the 50% conditioned medium (CM) from B103/APP cells but reduced by the CM from B103/APP delta NL cells. Chemically synthesized A beta at concentration levels higher than 1 nM reduced numbers of neurites from B103 or B103/APP delta NL cells. However, A beta at 1-100 nM could not reduce the neurite number of B103/APP cells. The protective activity against A beta's deleterious effect to reduce neurite numbers was attributed to sAPP alpha in the CM. Although sAPP alpha could block the effect of A beta, sAPP beta could not do so under the identical condition, suggesting the importance of the C-terminal 15-amino acid sequence in sAPP alpha. Nevertheless, sAPP alpha's protective activity required the N-terminal sequence around RERMS, previously identified to be the active domain of sAPP beta. The overall effect of APP mutation which overproduced A beta and sAPP beta and underproduced sAPP alpha was a marked decline in the neurotrophic effect of APP. We suggest that the disruption of balance between the detrimental effect of A beta and the trophic effect of sAPP may be important in the pathogenesis of AD caused by this pathogenic APP mutation.
authors.affiliation: Department of Neurosciences, University of California, San Diego, School of Medicine, La Jolla 92093-0624, USA.
authors.forename: H L
authors.initials: HL
authors.lastname: Li
authors.forename: J M
authors.initials: JM
authors.lastname: Roch
authors.forename: M
authors.initials: M
authors.lastname: Sundsmo
authors.forename: D
authors.initials: D
authors.lastname: Otero
authors.forename: S
authors.initials: S
authors.lastname: Sisodia
authors.forename: R
authors.initials: R
authors.lastname: Thomas
authors.forename: T
authors.initials: T
authors.lastname: Saitoh
mesh_terms: D000544:Alzheimer Disease / Q000235:genetics*; D016564:Amyloid beta-Protein Precursor / Q000737:chemistry / Q000235:genetics* / Q000378:metabolism; D000818:Animals; D019556:COS Cells / Q000502:physiology; D048429:Cell Size / Q000502:physiology; D002490:Central Nervous System / Q000166:cytology; D017077:Culture Media, Conditioned / Q000494:pharmacology; D005192:Family Health; D006801:Humans; D016296:Mutagenesis / Q000502:physiology; D016501:Neurites / Q000187:drug effects / Q000502:physiology*; D009474:Neurons / Q000737:chemistry / Q000166:cytology* / Q000648:ultrastructure; D017434:Protein Structure, Tertiary; D051381:Rats
chemical_list: D016564:Amyloid beta-Protein Precursor; D017077:Culture Media, Conditioned